BioXcel Drug Calms Agitation At Home For Schizophrenia, Bipolar Patients

All NewsSeptember 10, 2025

BioXcel’s Phase 3 trial shows BXCL501 effectively reduces agitation in bipolar and schizophrenia patients, supporting its at-home treatment use.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent